With PAMA scheduled to be implemented in January, many believe M&A in the clinical lab space will heat up, with Quest and LabCorp the main beneficiaries.
Multiple variant databases are creating competition among groups that disagree on how to advance the most scientifically robust and sustainable sharing model.
The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.
